Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

NCT01217450 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

NIH

Sponsor class

Conditions

Recurrent Colon Cancer
Recurrent Rectal Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer
Stage IVB Colon Cancer
Stage IVB Rectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: selumetinib
BIOLOGICAL: cetuximab
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)